Humonix Biosciences is a specialty pharma research company that uses an innovative platform technology to reduce the cost of ophthalmic drug development.
We have validated models for Glaucoma comprising of trabecular meshwork and/or the schlemm's canal cells, and for microvascular dysfunction in DR/DME that recapitulates the retinal microvasculature that incorporates human retinal pericytes cells
Glauconix’s 3D tissue system can reduce the risk of clinical trial failure; saving time, labor and development costs. Early identification and validation of effective compounds or biologics in species & disease relevant models, allows partners to confidently enter clinical trials.